InterMune Inc. (ITMN) Has Soared To A New High On Study Results

By RTT News, 
A A A
Share |


(RTTNews.com) - InterMune Inc. ( ITMN ) announced Tuesday morning that results from a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis, demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital capacity from Baseline to Week 52.

InterMune gapped open dramatically higher Tuesday and is now up 22.25 at $36.21 on strong volume. The stock has surged to a new high for the year.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com



This article appears in: News Headlines

Referenced Stocks: ITMN

RTT News


More from RTT News:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM